Transcranial Magnetic Therapy (TMS) for Treatment of Perinatal Depression
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07928908. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
TRANSCRANIAL MAGNETIC THERAPY (TMS) FOR TREATMENT OF PERINATAL DEPRESSION
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the use of transcranial magnetic stimulation (TMS) to treat depression during pregnancy and the first year after childbirth. TMS is a noninvasive treatment that uses magnetic pulses applied to the scalp to stimulate areas of the brain involved in depression. The main goal of the study is to determine whether TMS treatment is feasible, acceptable, and safe for women with perinatal depression. The study will also collect preliminary information about whether TMS reduces symptoms of depression and whether improvements are maintained after treatment. Up to 100 women age 22 years and older who have major depression and are either 12 to 28 weeks pregnant or within 12 months after giving birth will participate. All participants will receive TMS; there is no placebo or comparison group. Participants will receive 20 to 36 TMS treatment sessions over approximately 4 to 8 weeks, with up to five sessions per week. Depression and other mental health symptoms, treatment attendance, satisfaction with treatment, and safety will be assessed before, during, and approximately one month after TMS treatment. The study hypothesis is that TMS will be a feasible and acceptable treatment for women with perinatal depression, as shown by participants completing and adhering to treatment, acceptable treatment satisfaction, and appropriate safety outcomes. The study will also explore whether depressive symptoms improve during TMS treatment and whether improvement is sustained one month after treatment. For women who participate while pregnant, the study team will review maternal and infant medical records approximately six months after delivery to assess pregnancy, delivery, postpartum, and infant health outcomes.
Study identification
- NCT ID
- NCT07928908
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2026 (Actual)
- Primary completion
- Sep 2028 (Estimated)
- Completion
- May 2029 (Estimated)
- Last update posted
- Nov 10, 2026
2026 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Huntsman Mental Health Institute | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07928908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 10, 2026 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.